Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer

Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reapp...

Full description

Bibliographic Details
Main Authors: Lorena García-Hevia, Débora Muñoz-Guerra, Íñigo Casafont, Carmelo Morales-Angulo, Victor J. Ovejero, David Lobo, Mónica L. Fanarraga
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/10/4/732
_version_ 1797436839139737600
author Lorena García-Hevia
Débora Muñoz-Guerra
Íñigo Casafont
Carmelo Morales-Angulo
Victor J. Ovejero
David Lobo
Mónica L. Fanarraga
author_facet Lorena García-Hevia
Débora Muñoz-Guerra
Íñigo Casafont
Carmelo Morales-Angulo
Victor J. Ovejero
David Lobo
Mónica L. Fanarraga
author_sort Lorena García-Hevia
collection DOAJ
description Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.
first_indexed 2024-03-09T11:08:23Z
format Article
id doaj.art-b03c6de67d61466b8de6271ac2a9441d
institution Directory Open Access Journal
issn 2227-9059
language English
last_indexed 2024-03-09T11:08:23Z
publishDate 2022-03-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj.art-b03c6de67d61466b8de6271ac2a9441d2023-12-01T00:52:29ZengMDPI AGBiomedicines2227-90592022-03-0110473210.3390/biomedicines10040732Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck CancerLorena García-Hevia0Débora Muñoz-Guerra1Íñigo Casafont2Carmelo Morales-Angulo3Victor J. Ovejero4David Lobo5Mónica L. Fanarraga6The Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainServicio de Otorrinolaringología, Hospital Universitario Marqués de Valdecilla, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainThe Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011 Santander, SpainHead and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.https://www.mdpi.com/2227-9059/10/4/732gangliosidecancerresistancesquamous cell carcinoma
spellingShingle Lorena García-Hevia
Débora Muñoz-Guerra
Íñigo Casafont
Carmelo Morales-Angulo
Victor J. Ovejero
David Lobo
Mónica L. Fanarraga
Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
Biomedicines
ganglioside
cancer
resistance
squamous cell carcinoma
title Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
title_full Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
title_fullStr Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
title_full_unstemmed Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
title_short Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer
title_sort gb3 cd77 is a predictive marker and promising therapeutic target for head and neck cancer
topic ganglioside
cancer
resistance
squamous cell carcinoma
url https://www.mdpi.com/2227-9059/10/4/732
work_keys_str_mv AT lorenagarciahevia gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer
AT deboramunozguerra gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer
AT inigocasafont gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer
AT carmelomoralesangulo gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer
AT victorjovejero gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer
AT davidlobo gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer
AT monicalfanarraga gb3cd77isapredictivemarkerandpromisingtherapeutictargetforheadandneckcancer